The goal of antiretroviral therapy for the prevention of mother-to-child transmission (PMTCT) of HIV is to achieve maximal suppression of maternal viral load with minimal maternal, fetal and infant toxicity during pregnancy, delivery and postpartum. In addition to the efficacy and toxicity of antiretroviral therapy, the consideration of HIV resistance in mothers and infected newborns further complicates therapeutic choices for PMTCT. This manuscript summarizes current approaches to PMTC in diverse international settings.

Amntiretroviral, HIV, Perinatal, Prophylaxis
dx.doi.org/10.1016/S0378-3782(14)70005-2, hdl.handle.net/1765/88603
Early Human Development
Erasmus MC: University Medical Center Rotterdam

Rakhmanina, N.Y, & van den Anker, J.N. (2014). Pharmacologic prevention of perinatal HIV infection. Early Human Development (Vol. 90). doi:10.1016/S0378-3782(14)70005-2